Home/Filings/4/0001209191-23-053937
4//SEC Filing

Martin Daniel C. 4

Accession 0001209191-23-053937

CIK 0001654151other

Filed

Oct 30, 8:00 PM ET

Accepted

Oct 31, 4:10 PM ET

Size

6.9 KB

Accession

0001209191-23-053937

Insider Transaction Report

Form 4
Period: 2023-10-28
Martin Daniel C.
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2023-10-28+5,57664,291 total
  • Sale

    Common Stock

    2023-10-30$12.02/sh1,407$16,90962,884 total
Footnotes (3)
  • [F1]On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 5,576 RSUs.
  • [F2]Includes 302 shares previously acquired under the Issuer's 2017 Employee Stock Purchase Plan.
  • [F3]This sale was to cover tax liabilities in the vesting of RSUs.

Issuer

Deciphera Pharmaceuticals, Inc.

CIK 0001654151

Entity typeother

Related Parties

1
  • filerCIK 0001752827

Filing Metadata

Form type
4
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 4:10 PM ET
Size
6.9 KB